Technology
Health
Biotechnology

Aptevo

$0.98
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0607 (6.67%) Today
+$0.0093 (0.96%) After Hours

Why Robinhood?

You can buy or sell Aptevo and other stocks, options, ETFs, and crypto commission-free!

About

Aptevo Therapeutics Inc. Common Stock, also called Aptevo, is a biotechnology company, which engages in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics to improve patients lives. Read More Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Employees
118
Headquarters
Seattle, Washington
Founded
2016
Market Cap
20.76M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
205.43K
High Today
$1.03
Low Today
$0.8901
Open Price
$0.93
Volume
1.31M
52 Week High
$6.35
52 Week Low
$0.79

Collections

Technology
Health
Biotechnology
Therapy
2016 IPO
US
North America

News

Markets Insider20h

Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting

SEATTLE, March 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that preclinical data for two of its ADAPTIR™ bispecific antibody candidates will be presented in poster sessions at the American Association for Cancer Research (AACR) 2019 Annual Meeting, being held in Atlanta, GA, March 29 – April 3, 2019. Title: Preclinical safety and efficacy of a tumor-directed T ce...

252
Markets InsiderMar 18

Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update

Achieves Record Annual IXINITY® Net Revenue of $23.1 Million Representing 111% Increase Over 2017 Advances APVO436 Into Phase 1/1b Clinical Trial for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome Receives Authorization to Commence Dosing in Phase 1 Clinical Trial of APVO210; Dosing Scheduled to Begin March 2019 Progresses Novel 4-1BB/5T4 Bispecific Antibody ALG.APV-527 Towards CTA Filing in Q4 2019 SEATTLE, March 18, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq...

302
MarketBeatMar 17

Stock Price, News, & Analysis for Aptevo Therapeutics

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolyt...

0

Earnings

-$0.63
-$0.53
-$0.42
-$0.32
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.53 per share
Actual
Available Mar 18, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.